Literature DB >> 12457983

Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model.

Arthur R Frampton1, Patrick M Smith, Yunfei Zhang, Tomio Matsumura, Nikolaus Osterrieder, Dennis J O'Callaghan.   

Abstract

The pathogenesis of three equine herpesvirus 1 (EHV-1) recombinants was assessed in a CBA mouse model. Sequences encoding the majority of glycoproteins I (gI) and E (gE) were deleted from the pathogenic EHV-1 strain RacL11 (L11deltagIdeltagE), and sequences comprising the 3859 bp deletion within the strain KyA U(S) segment, which includes genes 73 (gI), 74 (gE), and 75 (putative 10 kDa protein 75), were re-inserted into attenuated KyA (KgI/gE/75). In addition, genes gE and 75 were inserted into KyA to generate the EHV-1 recombinant KgE/75. The insertion of the 3859 bp U(S) segment was sufficient to confer virulence to KyA, as indicated by pronounced signs of clinical disease including substantial weight loss. A large plaque morphology was observed in cells infected with KgI/gE/75 compared with KyA, and a small plaque phenotype was observed in cells infected with L11deltagIdeltagE compared with RacL11. These data indicate that gI and/or gI and gE contribute to the ability of EHV-1 to spread directly from cell-to-cell. The deletion of both gI and gE from the pathogenic RacL11 strain did not reduce clinical signs of disease in infected mice, but did decrease mortality compared with RacL11. Furthermore, the insertion of genes 74 (gE) and 75 into the vaccine strain KyA did not alter the attenuated phenotype of this virus. Finally, KgI/gE/75 and RacL11 elicited the production of the proinflammatory chemokines MIP-1alpha, MIP-1beta, and MIP-2 in the lungs of infected mice, while KyA did not, suggesting that gI and/or gI and gE contribute to the up-regulation of these mediators of inflammation. These findings show that gI, and/or gI and gE restore a virulent phenotype to the EHV-1 KyA strain, and indicate that virulence factors, in addition to gI and gE, contribute to the pathogenesis of the RacL11 strain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12457983     DOI: 10.1016/s0168-1702(02)00245-9

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  17 in total

1.  Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1.

Authors:  Arthur R Frampton; Donna B Stolz; Hiroaki Uchida; William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Immunization with Attenuated Equine Herpesvirus 1 Strain KyA Induces Innate Immune Responses That Protect Mice from Lethal Challenge.

Authors:  Seong K Kim; Akhalesh K Shakya; Dennis J O'Callaghan
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

3.  Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells.

Authors:  Michael J Courchesne; Maria C White; Brent A Stanfield; Arthur R Frampton
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

4.  Expression of the full-length form of gp2 of equine herpesvirus 1 (EHV-1) completely restores respiratory virulence to the attenuated EHV-1 strain KyA in CBA mice.

Authors:  Patrick M Smith; Shannon M Kahan; Colin B Rorex; Jens von Einem; Nikolaus Osterrieder; Dennis J O'Callaghan
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Properties of an equine herpesvirus 1 mutant devoid of the internal inverted repeat sequence of the genomic short region.

Authors:  ByungChul Ahn; Yunfei Zhang; Nikolaus Osterrieder; Dennis J O'Callaghan
Journal:  Virology       Date:  2010-12-21       Impact factor: 3.616

6.  Equus caballus major histocompatibility complex class I is an entry receptor for equine herpesvirus type 1.

Authors:  Brian M Kurtz; Lauren B Singletary; Sean D Kelly; Arthur R Frampton
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells.

Authors:  Arthur R Frampton; Hiroaki Uchida; Jens von Einem; William F Goins; Paola Grandi; Justus B Cohen; Nikolaus Osterrieder; Joseph C Glorioso
Journal:  Vet Microbiol       Date:  2009-08-08       Impact factor: 3.293

8.  CCL3 and viral chemokine-binding protein gg modulate pulmonary inflammation and virus replication during equine herpesvirus 1 infection.

Authors:  Gerlinde R Van de Walle; Kaori Sakamoto; Nikolaus Osterrieder
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

9.  The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11.

Authors:  Jens von Einem; Janet Wellington; J Millar Whalley; Kerstin Osterrieder; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Effective treatment of respiratory alphaherpesvirus infection using RNA interference.

Authors:  Amy Fulton; Sarah T Peters; Gillian A Perkins; Keith W Jarosinski; Armando Damiani; Margaret Brosnahan; Elizabeth L Buckles; Nikolaus Osterrieder; Gerlinde R Van de Walle
Journal:  PLoS One       Date:  2009-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.